Tumori · 2025
An indirect approach to identify the healthcare services for thyroid and melanoma cancer patients in Italy: Epicost-2 project.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Mallone Sandra, Tavilla Andrea, Lopez Tania, Pierannunzio Daniela, Dal Maso Luigino, Guzzinati Stefano, Fedeli Ugo, Gagliani Alberto, Buja Alessandra, Zorzi Manuel, Fusco Mario, Toffolutti Federica, Francisci Silvia
Аннотация
INTRODUCTION: An indirect approach was applied to the case-study of thyroid cancer (TC) and melanoma of the skin (MS) in Italy to identify health services (HS) for cancer patients and to enable cost estimation.
MATERIALS AND METHODS: Within the Epicost-2 project, a self-controlled crossover design analysed TC and MS 2018 prevalent cases from Italian cancer registries. Controls (1:1) were matched to cases 18-6 months prior to diagnosis; increases between cases and controls in potentially cancer-related HS claims (P⩽5%) were identified.
VALIDATION: Oncology and clinical experts validated cancer-related HS lists using statistical, clinical, and economic criteria.
RESULTS: The approach identified 202 and 333 cancer-related HS codes for TC and MS, respectively, aligned with clinical pathways.
DISCUSSION: The indirect approach reduced validation workload by 75% versus direct one.
CONCLUSION: The approach identifies the costs of cancer care that could also be reproduced in other countries with consistent results, and the approach applied to other cancers.
MATERIALS AND METHODS: Within the Epicost-2 project, a self-controlled crossover design analysed TC and MS 2018 prevalent cases from Italian cancer registries. Controls (1:1) were matched to cases 18-6 months prior to diagnosis; increases between cases and controls in potentially cancer-related HS claims (P⩽5%) were identified.
VALIDATION: Oncology and clinical experts validated cancer-related HS lists using statistical, clinical, and economic criteria.
RESULTS: The approach identified 202 and 333 cancer-related HS codes for TC and MS, respectively, aligned with clinical pathways.
DISCUSSION: The indirect approach reduced validation workload by 75% versus direct one.
CONCLUSION: The approach identifies the costs of cancer care that could also be reproduced in other countries with consistent results, and the approach applied to other cancers.